Literature DB >> 21291686

Making a case for quantitative assessment of cardiovascular risk.

Peter P Toth1.   

Abstract

Cardiovascular disease (CVD) causes nearly one third of all deaths worldwide. Estimates of the cumulative effects of the most common cardiovascular risk factors indicate that >30% of the chronic care burden of CVD and >50% of deaths from CVD are attributable to modifiable risk factors, such as cigarette smoking, elevated low-density lipoprotein cholesterol, low levels of high-density lipoprotein cholesterol, diabetes mellitus, and hypertension. While a significant percentage of patients present with one or more of these risk factors, health care practitioners encounter great difficulty in achieving long-term patient adherence to risk-factor modification interventions. More accurate stratification of death and disability risk across age, gender, and ethnic categories-and more comprehensible quantification of the magnitude and timeframe of the impact of risk-factor modification on such risks-will likely be useful to patients and health care practitioners in the implementation of more effective strategies. There is a need to study which risk-assessment methodologies, which depictions of short- and long-term risk, and which intervention modalities will have the greatest possible impact on patients' understanding of risk factors and risk-modification behaviors.

Entities:  

Year:  2007        PMID: 21291686     DOI: 10.1016/j.jacl.2007.07.002

Source DB:  PubMed          Journal:  J Clin Lipidol        ISSN: 1876-4789            Impact factor:   4.766


  11 in total

Review 1.  Antioxidant and anti-inflammatory medicinal plants have potential role in the treatment of cardiovascular disease: a review.

Authors:  Peter Adegbola; Ifewumi Aderibigbe; Wasiu Hammed; Tolulope Omotayo
Journal:  Am J Cardiovasc Dis       Date:  2017-04-15

Review 2.  Drug treatment of hyperlipidaemia: a guide to the rational use of lipid-lowering drugs.

Authors:  Peter P Toth
Journal:  Drugs       Date:  2010-07-30       Impact factor: 9.546

3.  Lipoprotein associated phospholipase A(2): role in atherosclerosis and utility as a biomarker for cardiovascular risk.

Authors:  Kenneth J Colley; Robert L Wolfert; Michael E Cobble
Journal:  EPMA J       Date:  2011-03-10       Impact factor: 6.543

Review 4.  Prevention and Treatment of Cardiovascular Diseases with Plant Phytochemicals: A Review.

Authors:  Rakesh Kumar Bachheti; Limenew Abate Worku; Yilma Hunde Gonfa; Meseret Zebeaman; D P Pandey; Archana Bachheti
Journal:  Evid Based Complement Alternat Med       Date:  2022-07-04       Impact factor: 2.650

Review 5.  A review on the medicinal potentials of ginseng and ginsenosides on cardiovascular diseases.

Authors:  Chang Ho Lee; Jong-Hoon Kim
Journal:  J Ginseng Res       Date:  2014-04-03       Impact factor: 6.060

Review 6.  Pharmacological and medical applications of Panax ginseng and ginsenosides: a review for use in cardiovascular diseases.

Authors:  Jong-Hoon Kim
Journal:  J Ginseng Res       Date:  2017-10-21       Impact factor: 6.060

Review 7.  Herbal Medicine for Cardiovascular Diseases: Efficacy, Mechanisms, and Safety.

Authors:  Abdullah Shaito; Duong Thi Bich Thuan; Hoa Thi Phu; Thi Hieu Dung Nguyen; Hiba Hasan; Sarah Halabi; Samar Abdelhady; Gheyath K Nasrallah; Ali H Eid; Gianfranco Pintus
Journal:  Front Pharmacol       Date:  2020-04-07       Impact factor: 5.810

8.  An independent external validation and evaluation of QRISK cardiovascular risk prediction: a prospective open cohort study.

Authors:  Gary S Collins; Douglas G Altman
Journal:  BMJ       Date:  2009-07-07

9.  Cardiovascular Diseases and Panax ginseng: A Review on Molecular Mechanisms and Medical Applications.

Authors:  Jong-Hoon Kim
Journal:  J Ginseng Res       Date:  2012-01       Impact factor: 6.060

10.  Synergistic effects of colchicine combined with atorvastatin in rats with hyperlipidemia.

Authors:  Congwu Huang; Chuan Cen; ChengXu Wang; Haiyong Zhan; Xin Ding
Journal:  Lipids Health Dis       Date:  2014-04-17       Impact factor: 3.876

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.